| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | -0.066 | 0.09 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.052 | 0.09 |
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | 0.056 | 0.09 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.051 | 0.09 |
| mRNA | QL-XII-61 | GDSC1000 | pan-cancer | AAC | 0.082 | 0.09 |
| mRNA | 681640 | GDSC1000 | pan-cancer | AAC | 0.064 | 0.09 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.078 | 0.09 |
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | 0.059 | 0.09 |
| mRNA | XMD13-2 | GDSC1000 | pan-cancer | AAC | -0.052 | 0.09 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.057 | 0.1 |